Cancer Immunology Research

Cancer Immunology Research publishes outstanding original articles reporting major advances in cancer immunology, spanning the discipline from basic investigations of host-tumor interactions to clinical trials of immunotherapies.《癌症免疫学研究》（Cancer Immunology Research）发表报告癌症免疫学重大进展的优秀原创论文，涵盖从宿主—肿瘤相互作用基础研究到免疫治疗临床试验的整个学科。

Scope

The journal's stated aim is to disseminate knowledge of immunology to the cancer research community and catalyse cross-disciplinary work, with its official scope covering:刊物官方宗旨为向癌症研究共同体传播免疫学知识并推动跨学科工作，官方声明的征稿范围包括：

• Basic tumor immunology: investigations of host-tumor interactions, including tumor antigens, immune recognition, tumor immune evasion mechanisms, the tumor microenvironment, and the regulation of innate and adaptive immune responses to cancer.基础肿瘤免疫学： 宿主—肿瘤相互作用研究，涵盖肿瘤抗原、免疫识别、肿瘤免疫逃逸机制、肿瘤微环境以及对癌症的固有与适应性免疫应答调控等。
• Preclinical therapeutic development: studies in model systems of cancer immunotherapies, including immune checkpoint blockade, adoptive cell therapy, cancer vaccines, oncolytic viruses, and the combination of immunotherapies with other treatment modalities.临床前治疗开发： 癌症免疫治疗在模型系统中的研究，涵盖免疫检查点阻断、过继细胞治疗、癌症疫苗、溶瘤病毒以及免疫治疗与其他治疗方式的联合应用等。
• Translational and clinical immunology: early translational studies in patients and late-stage clinical trials of cancer immunotherapies, including biomarker discovery, patient stratification, resistance mechanisms, and the clinical evaluation of new immunotherapy agents and regimens.转化与临床免疫学： 患者中的早期转化研究与癌症免疫治疗的后期临床试验，涵盖生物标志物发现、患者分层、耐药机制以及新免疫治疗药物和方案的临床评价等。
• Cross-disciplinary interface: work that bridges immunology with cancer biology, genomics, computational biology, and engineering, yielding a deeper understanding of the host-tumor relationship and more potent cancer treatments.交叉学科界面： 衔接免疫学与癌症生物学、基因组学、计算生物学和工程学的工作，旨在深化对宿主—肿瘤关系的理解并开发更有效的癌症治疗方法。
• Article types: original research articles, reviews, perspectives, and editorials, with an emphasis on findings that advance the understanding and treatment of cancer through immunological approaches.栏目设置： 接受原创研究论文、综述、观点与社论，强调通过免疫学方法推动癌症理解与治疗的研究发现。

History

• Founding: the journal was launched in 2013 by the American Association for Cancer Research to provide a dedicated venue for the rapidly growing field of cancer immunology and immunotherapy.创刊： 该刊 2013 年由美国癌症研究协会创刊，旨在为快速发展的癌症免疫学与免疫治疗领域提供专门平台。
• Founding editor: the journal was established under the leadership of its founding editor-in-chief, who set out its mission to become the leading publication for the full spectrum of cancer immunology research.创刊主编： 该刊在创刊主编的领导下创立，确立了成为癌症免疫学研究全谱系一流发表平台的使命。
• Editorial succession: Elizabeth M. Jaffee and Antoni Ribas were appointed as editors-in-chief, bringing their expertise in cancer vaccines and tumor immunology and in immunotherapy clinical development respectively to guide the journal's direction.编辑交接： 伊丽莎白·贾菲（Elizabeth M. Jaffee）与安东尼·里瓦斯（Antoni Ribas）被任命为主编，分别凭借其在癌症疫苗与肿瘤免疫学以及免疫治疗临床开发方面的专长指引刊物方向。

Editors

The journal is led by two editors-in-chief supported by associate editors and an editorial board, drawn from cancer immunology and immunotherapy institutions worldwide:该刊由两位主编领导，副编辑与编委会协助，成员来自全球癌症免疫学与免疫治疗机构：

• Editors-in-chief: Elizabeth M. Jaffee of the Johns Hopkins University School of Medicine, whose research focuses on cancer vaccines and immune-based therapies for pancreatic and other cancers. Antoni Ribas of the University of California, Los Angeles, whose research focuses on the immunotherapy of melanoma and the mechanisms of response and resistance to immune checkpoint inhibitors.主编： 约翰斯·霍普金斯大学医学院的伊丽莎白·贾菲（Elizabeth M. Jaffee），研究方向为胰腺癌及其他癌症的癌症疫苗与免疫治疗；加州大学洛杉矶分校的安东尼·里瓦斯（Antoni Ribas），研究方向为黑色素瘤免疫治疗以及对免疫检查点抑制剂应答与耐药的机制。
• Associate editors: associate editors cover basic tumor immunology, preclinical therapeutics, translational immunology, clinical trials, and computational immunology, supporting manuscript handling across the journal's scope.副编辑团队： 副编辑覆盖基础肿瘤免疫学、临床前治疗、转化免疫学、临床试验与计算免疫学等方向，协助处理刊物范围内的稿件。
• Review model: manuscripts undergo single-blind peer review by external experts, with final decisions made by the editors-in-chief and associate editors based on scientific quality, novelty, and significance to the cancer immunology field.评审模式： 稿件由外部专家进行单盲同行评审，主编与副编辑基于科学质量、新颖性以及对癌症免疫学领域的重要性做出最终决定。